PBAC Public Summary Documents – March 2022

Page last updated: 30 June 2022

Public Summary Documents relating to the March 2022 PBAC meeting.

• Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio™
• Abiraterone and methylprednisolone: Pack containing 120 tablets abiraterone (as acetate) 125 mg and 60 tablets methylprednisolone 4 mg; Yonsa® MPRED
• Amifampridine: Tablet 10 mg; Ruzurgi®
• Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®
• Beclometasone with formeterol: Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose; Fostair®
• Beclometasone with formoterol and glycopyrronium: Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses, Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses; Trimbow®
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Bevaciptin®
• Bimekizumab: Solution for injection 160 mg in 1 mL pre-filled pen, Solution for injection 160 mg in 1 mL pre-filled syringe; Bimzelx®
• Bortezomib: Solution for Injection 2.5 mg, Solution for Injection 3.5 mg; Bortezomib Ever Pharma®
• Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita®
• Cabazitaxel: Solution concentrate for I.V. infusion 60 mg in 3 mL; Cabazitaxel Accord®
• Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex®
• Carfilzomib: Powder for injection 10 mg, Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis®
• Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
• Ciclosporin: Eye drops 900 micrograms per mL, single dose units, 0.25 mL, 60; Cequa®
• Dapagliflozin: Tablet 10 mg; Forxiga®
• Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine (DTPa-HB-IPV-Hib): 0.5 mL pre-filled syringe; Vaxelis™
• Diroximel fumarate: Capsule 231 mg; Vumerity®
• Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
• Dorzolamide with timolol: Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL; VIzo-PF Dorzolatim®
• Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent®
• Durvalumab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®
• Enfortumab vedotin: Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev®
• Enzalutamide: Capsule 40 mg; Xtandi®
• Fremanezumab (auto-injector): Solution for injection 225 mg in 1.5 mL single dose auto-injector; Ajovy®
• Fremanezumab (pre-filled syringe): Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy®
• Galcanezumab: Injection 120 mg in 1 mL pre-filled pen; Emgality®
• Gilteritinib: Tablet 40 mg (as fumarate); Xospata®
• Glatiramer: Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled pen; Copaxone®
• Glycomacropeptide formula with amino acids and low phenylalanine: Sachets containing oral powder 12.5 g, 30; PKU GMPro MIX-IN®
• Glycomacropeptide formula with amino acids, vitamins, minerals, trace elements, carbohydrate, fat and low phenylalanine: Sachets containing oral powder 33.4 g, 30; PKU GMPro ULTRA®
• Infliximab: Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC
• Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro®
• Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi®
• Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex®
• Methylphenidate: Capsule containing methylphenidate hydrochloride 10 mg (modified release), Capsule containing methylphenidate hydrochloride 20 mg (modified release), Capsule containing methylphenidate hydrochloride 30 mg (modified release), Capsule containing methylphenidate hydrochloride 40 mg (modified release), Capsule containing methylphenidate hydrochloride 60 mg (modified release); Ritalin® LA
• Niraparib: Capsule 100 mg; Zejula®
• Nivolumab (HER-2-neg gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
• Nivolumab (Second-line squamous cell oesophageal carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza®
• Ozanimod: Capsule 920 micrograms, Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms; Zeposia®
• Palbociclib: Tablet 75 mg, Tablet 100 mg, Tablet 125 mg; Ibrance®
• Paliperidone: I.M. injection (modified release) 700 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 1000 mg (as palmitate) in pre-filled syringe; Invega Hafyera®
• Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™
• Pembrolizumab (Renal cell carcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
• Pembrolizumab (Oesophageal carcinoma or HER-2-neg gastroesophageal junction adenocarcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
• Pembrolizumab (Endometrial cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2023
• Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
• Rabeprazole: Tablet containing rabeprazole sodium 20 mg (enteric coated); Pariet®
• Risankizumab (Psoriatic arthritis): Injection 150 mg in 1 mL pre-filled syringe, Injection 150 mg in 1 mL pre-filled pen; Skyrizi®
• Risankizumab (Severe chronic plaque psoriasis): Injection 150 mg in 1 mL pre-filled pen, Injection 150 mg in 1 mL pre-filled syringe, Injection 75 mg in 0.83 mL pre-filled syringe; Skyrizi®
• Sacituzumab govitecan: Powder for injection 180 mg; Trodelvy®
• Sebelipase alfa: Solution concentrate for I.V. infusion 20 mg in 10 mL; Kanuma®
• Secukinumab: Solution for injection 300 mg in 2 mL pre-filled pen, Solution for injection 300 mg in 2 mL pre-filled syringe; Cosentyx®
• Selinexor (RR MM): Tablet 20 mg; Xpovio®
• Selinexor (TCR PR MM): Tablet 20 mg; Xpovio®
• Semaglutide: Injection 0.25 mg in 0.5 mL pre-filled single dose pen, Injection 0.5 mg in 0.5 mL pre-filled single dose pen, Injection 1.0 mg in 0.5 mg pre-filled single dose pen, Injection 1.7 mg in 0.75 mL pre-filled single dose pen, Injection 2.4 mg in 0.75 mL pre-filled single dose pen; Wegovy®
• Somatrogon: Injection 24 mg in 1.2 mL pre-filled single-use pen, Injection 60 mg in 1.2 mL pre-filled single-use pen; Ngenla®
• Somapacitan: Injection 10 mg in 1.5 mL pre-filled pen; Sogroya®
• Sotorasib: Tablet 120 mg; Lumakras®
• Tepotinib: Tablet 225 mg (as hydrochloride monohydrate); Tepmetko®
• Trientine: Tablet 150 mg (as tetrahydrochloride); Cuprior®
• Trientine: Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine); Waymade®
• Triglycerides, medium chain: Oral liquid 225 mL, 15; K.Quik®
• Vericiguat: Tablet 2.5 mg, Tablet 5 mg, Tablet 10 mg; Verquvo®
• Zanubrutinib: Capsule 80 mg; Brukinsa®